Xospata Approved to Treat Acute Myeloid Leukemia
November 28, 2018Truxima, First Rituxan Biosimilar, Approved
November 28, 2018EpiPen Generics Launched
November 28, 2018 – Teva Pharmaceuticals has launched limited quantities of its generic for Mylan's EpiPen® (epinephrine 0.3mg) auto-injectors. Epinephrine auto-injectors are approved to provide emergency treatment of allergic reactions, including anaphylaxis.
The release of Teva’s generic epinephrine auto-injectors may help ease drug shortages, which have affected the EpiPen and similar products in recent years. Other available epinephrine auto-injectors include:
- Impax Laboratories' Adrenaclick® (epinephrine 0.3mg) and its authorized generic;
- Mylan's authorized generics for its EpiPen and EpiPen Jr® (epinephrine 0.15mg); and
- Kaleo's Auvi-Q®, available in both 0.3mg and 0.15mg dosage strengths.
Teva's generic has been launched at a wholesale acquisition cost of $300 for a package of two injectors, the same price as Mylan's authorized generic for the EpiPen.
